ATE449604T1 - Pyrazolamid-derivate, diese verbindungen enthaltende zusammensetzungen und anwendungsverfahren - Google Patents
Pyrazolamid-derivate, diese verbindungen enthaltende zusammensetzungen und anwendungsverfahrenInfo
- Publication number
- ATE449604T1 ATE449604T1 AT05764518T AT05764518T ATE449604T1 AT E449604 T1 ATE449604 T1 AT E449604T1 AT 05764518 T AT05764518 T AT 05764518T AT 05764518 T AT05764518 T AT 05764518T AT E449604 T1 ATE449604 T1 AT E449604T1
- Authority
- AT
- Austria
- Prior art keywords
- compounds
- methods
- pyrazolamide
- derivatives
- compositions containing
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- BNYCHCAYYYRJSH-UHFFFAOYSA-N 1h-pyrazole-5-carboxamide Chemical class NC(=O)C1=CC=NN1 BNYCHCAYYYRJSH-UHFFFAOYSA-N 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- -1 Pyrazole amides Chemical class 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Neurology (AREA)
- Ophthalmology & Optometry (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Detergent Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US58604704P | 2004-07-07 | 2004-07-07 | |
| PCT/US2005/023684 WO2006017055A2 (en) | 2004-07-07 | 2005-07-01 | Pyrazole amide derivatives, compositions containing such compounds and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE449604T1 true ATE449604T1 (de) | 2009-12-15 |
Family
ID=35839709
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT05764518T ATE449604T1 (de) | 2004-07-07 | 2005-07-01 | Pyrazolamid-derivate, diese verbindungen enthaltende zusammensetzungen und anwendungsverfahren |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US7649009B2 (de) |
| EP (1) | EP1765335B1 (de) |
| JP (1) | JP2008505905A (de) |
| CN (1) | CN1980665A (de) |
| AT (1) | ATE449604T1 (de) |
| AU (1) | AU2005272043B2 (de) |
| CA (1) | CA2572745A1 (de) |
| DE (1) | DE602005017895D1 (de) |
| WO (1) | WO2006017055A2 (de) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101522623B (zh) * | 2006-08-03 | 2013-06-12 | 塔夫茨大学信托人 | 无潮红烟酸类似物和其使用方法 |
| PT2129654E (pt) | 2007-02-09 | 2014-09-04 | Metabasis Therapeutics Inc | Antagonistas do receptor de glucagina |
| NZ588011A (en) * | 2008-03-05 | 2012-06-29 | Takeda Pharmaceutical | Heterocyclic compounds having glucagon antagonistic action useful for treating diabetes |
| JP2011520897A (ja) | 2008-05-16 | 2011-07-21 | シェーリング コーポレイション | グルカゴン受容体アンタゴニスト、組成物およびそれらの使用方法 |
| CA2724430A1 (en) * | 2008-05-19 | 2009-11-26 | Schering Corporation | Heterocyclic compounds as factor ixa inhibitors |
| MX2011001708A (es) | 2008-08-13 | 2011-04-26 | Metabasis Therapeutics Inc | Antagonistas de glucagon. |
| EP2346830B1 (de) | 2008-09-15 | 2015-05-13 | Merck Sharp & Dohme Corp. | Den glucagonrezeptor antagonisierende verbindungen, zusammensetzungen, die solche verbindungen enthalten, und anwendungsverfahren |
| WO2010039789A1 (en) * | 2008-10-03 | 2010-04-08 | Schering Corporation | Spiro-imidazolone derivatives as glucagon receptor antagonists |
| WO2010093535A1 (en) | 2009-02-12 | 2010-08-19 | Merck Sharp & Dohme Corp. | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use |
| US8318667B2 (en) | 2009-02-25 | 2012-11-27 | Merck Sharp & Dohme Corp. | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use |
| US8470773B2 (en) | 2009-06-12 | 2013-06-25 | Merck Sharp & Dohme Corp. | Thiophenes as glucagon receptor antagonists, compositions, and methods for their use |
| WO2011037815A1 (en) | 2009-09-22 | 2011-03-31 | Schering Corporation | Novel pyrrolidines as glucagon receptor antagonists, compositions, and methods for their use |
| WO2012030165A2 (ko) | 2010-08-31 | 2012-03-08 | 서울대학교산학협력단 | P P A R δ 활성물질의 태자재프로그래밍용도 |
| WO2012085745A1 (en) | 2010-12-23 | 2012-06-28 | Pfizer Inc. | Glucagon receptor modulators |
| PT2673260T (pt) | 2011-02-08 | 2016-10-24 | Pfizer | Modulador do recetor de glucagon |
| JP5647379B2 (ja) | 2011-07-22 | 2014-12-24 | ファイザー・インク | キノリニルグルカゴン受容体モジュレーター |
| CA2882292C (en) | 2012-08-13 | 2023-10-17 | The Rockefeller University | Treatment and diagnosis of melanoma |
| TW201427658A (zh) | 2012-12-10 | 2014-07-16 | Merck Sharp & Dohme | 藉由投予升糖素受體拮抗劑及膽固醇吸收抑制劑治療糖尿病之方法 |
| US9649294B2 (en) | 2013-11-04 | 2017-05-16 | Merck Sharp & Dohme Corp. | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use |
| JP2017519000A (ja) | 2014-06-12 | 2017-07-13 | リガンド・ファーマシューティカルズ・インコーポレイテッド | グルカゴンアンタゴニスト |
| WO2016057322A1 (en) * | 2014-10-08 | 2016-04-14 | Salk Institute For Biological Studies | Ppar agonists and methods of use thereof |
| CA3010883A1 (en) | 2016-01-11 | 2017-07-20 | The Rockefeller University | Methods for the treatment of myeloid derived suppressor cells related disorders |
| KR102708864B1 (ko) | 2016-08-30 | 2024-09-25 | 리제너론 파마슈티칼스 인코포레이티드 | 글루카곤 수용체 신호전달을 간섭함에 의한 중증 인슐린 저항성의 치료 방법 |
| US20190248888A1 (en) | 2016-10-20 | 2019-08-15 | Regeneron Pharmaceuticals, Inc. | Methods of lowering blood glucose levels |
| JP7781519B2 (ja) | 2017-08-22 | 2025-12-08 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | グルカゴン受容体シグナル伝達に干渉することによって尿素サイクル異常症を治療する方法 |
| EP3713575A4 (de) | 2017-11-21 | 2021-08-25 | Rgenix, Inc. | Polymorphe und ihre verwendung |
| JP2021513564A (ja) | 2018-02-13 | 2021-05-27 | リガンド・ファーマシューティカルズ・インコーポレイテッド | グルカゴン受容体拮抗薬 |
| TWI805699B (zh) | 2018-03-01 | 2023-06-21 | 日商日本煙草產業股份有限公司 | 甲基內醯胺環化合物及其用途 |
| MX2020010433A (es) | 2018-04-04 | 2020-10-28 | Japan Tobacco Inc | Compuestos de pirazol sustituidos con heteroarilo y uso farmaceutico de los mismos. |
| JP7689964B2 (ja) | 2019-12-13 | 2025-06-09 | インスピルナ，インコーポレーテッド | 金属塩及びその使用 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH11508267A (ja) * | 1995-06-26 | 1999-07-21 | 藤沢薬品工業株式会社 | ピラゾール化合物および医薬組成物 |
| US6825011B1 (en) | 1998-12-17 | 2004-11-30 | Yuri Rumantichikov | Methods for insertion of nucleic acids into circular vectors |
| AR008789A1 (es) * | 1996-07-31 | 2000-02-23 | Bayer Corp | Piridinas y bifenilos substituidos |
| US5776954A (en) * | 1996-10-30 | 1998-07-07 | Merck & Co., Inc. | Substituted pyridyl pyrroles, compositions containing such compounds and methods of use |
| EP0959885A4 (de) | 1996-11-20 | 2002-07-17 | Merck & Co Inc | Triaryl substituierte imidazole und verfahren zur verwendung |
| EP0959886A4 (de) | 1996-11-20 | 2001-05-02 | Merck & Co Inc | Triaryl substituierte imidazole als glucagon antagonisten |
| JP2001504490A (ja) | 1996-11-20 | 2001-04-03 | メルク エンド カンパニー インコーポレーテッド | トリアリール置換イミダゾール、そのような化合物を含む組成物及び使用方法 |
| US6613942B1 (en) * | 1997-07-01 | 2003-09-02 | Novo Nordisk A/S | Glucagon antagonists/inverse agonists |
| US6174901B1 (en) * | 1998-12-18 | 2001-01-16 | Amgen Inc. | Substituted pyridine and pyridazine compounds and methods of use |
| US6503949B1 (en) * | 1999-05-17 | 2003-01-07 | Noro Nordisk A/S | Glucagon antagonists/inverse agonists |
| PL356487A1 (en) * | 1999-11-10 | 2004-06-28 | Takeda Chemical Industries, Ltd. | 5-membered n-heterocyclic compounds with hypoglycemic and hypolipidemic activity |
| US6562807B2 (en) * | 2000-06-23 | 2003-05-13 | Novo Nordisk A/S | Glucagon antagonists/inverse agonists |
| US20030203946A1 (en) * | 2000-11-17 | 2003-10-30 | Carsten Behrens | Glucagon antagonists/inverse agonists |
| WO2002040444A1 (en) | 2000-11-17 | 2002-05-23 | Novo Nordisk A/S | Glucagon antagonists/inverse agonists |
| US6881746B2 (en) * | 2001-12-03 | 2005-04-19 | Novo Nordick A/S | Glucagon antagonists/inverse agonists |
| WO2003051357A1 (en) | 2001-12-19 | 2003-06-26 | Novo Nordisk A/S | Glucagon receptor antagonists/inverse agonists |
| US20060116366A1 (en) * | 2002-12-04 | 2006-06-01 | Parmee Emma R | Spirocyclic ureas, compositions containing such compounds and methods of use |
| DE602004030318D1 (de) * | 2003-01-27 | 2011-01-13 | Merck Sharp & Dohme | Substituierte pyrazole, zusammensetzungen,die solche verbindungen enthalten, und anwendungsverfahren |
-
2005
- 2005-07-01 JP JP2007520421A patent/JP2008505905A/ja not_active Ceased
- 2005-07-01 WO PCT/US2005/023684 patent/WO2006017055A2/en not_active Ceased
- 2005-07-01 EP EP05764518A patent/EP1765335B1/de not_active Expired - Lifetime
- 2005-07-01 DE DE602005017895T patent/DE602005017895D1/de not_active Expired - Lifetime
- 2005-07-01 CN CNA2005800230642A patent/CN1980665A/zh active Pending
- 2005-07-01 US US11/631,580 patent/US7649009B2/en not_active Expired - Fee Related
- 2005-07-01 AT AT05764518T patent/ATE449604T1/de not_active IP Right Cessation
- 2005-07-01 AU AU2005272043A patent/AU2005272043B2/en not_active Ceased
- 2005-07-01 CA CA002572745A patent/CA2572745A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1765335A2 (de) | 2007-03-28 |
| WO2006017055A2 (en) | 2006-02-16 |
| EP1765335B1 (de) | 2009-11-25 |
| AU2005272043B2 (en) | 2010-07-29 |
| US20070203186A1 (en) | 2007-08-30 |
| WO2006017055A3 (en) | 2006-08-10 |
| US7649009B2 (en) | 2010-01-19 |
| DE602005017895D1 (de) | 2010-01-07 |
| JP2008505905A (ja) | 2008-02-28 |
| CA2572745A1 (en) | 2006-02-16 |
| AU2005272043A1 (en) | 2006-02-16 |
| CN1980665A (zh) | 2007-06-13 |
| EP1765335A4 (de) | 2009-03-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE449604T1 (de) | Pyrazolamid-derivate, diese verbindungen enthaltende zusammensetzungen und anwendungsverfahren | |
| MY143599A (en) | Pyrazole derivatives, compositions containing such compounds and methods of use | |
| ATE368031T1 (de) | Neue gamma secretase inhibitoren | |
| DE602004009295D1 (de) | 1,2,3-trisubstituierte aryl- und heteroarylderivate als modulatoren des metabolismus zur vorbeugung und behandlung von metabolismus-bedingten krankheiten wie diabetes oder hyperglykämie | |
| TN2009000111A1 (en) | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use | |
| ATE516286T1 (de) | 5-(ä1,3,4üoxadiazol-2-yl)-1h-indazol und 5-(ä1,3, 4üthiadiazol-2-yl)-1h-indazol derivate als sgk- inhibitoren zur behandlung von diabetes | |
| NO20070049L (no) | Pyrrolotriazinderivater anvendelig for behandling av hyperproliferative forstyrrelser og sykdommer assosiert med angiogenese | |
| DE602004007693D1 (de) | (3-oxo-3,4-dihydro-chinoxalin-2-yl-amino)-benzamid-derivate und verwandte verbindungen als glykogen-phosphorylase-hemmer zur behandlung von diabetes und adipositas | |
| ATE433447T1 (de) | Pyrimiidinverbindungen | |
| ATE504565T1 (de) | Azetidine als mek-inhibitoren bei der behandlung proliferativer erkrankungen | |
| NO20064325L (no) | Heteroarylaminopyrazolderivativer nyttige for behandling av diabetes | |
| EA200700489A1 (ru) | Новые бензоконденсированные гетероарилсульфамидные производные, полезные в качестве противоконвульсивных средств | |
| ATE350377T1 (de) | Substituierte 3-pyrrolidin-indol-derivate | |
| ATE384058T1 (de) | Thiazolderivate | |
| SE0403006D0 (sv) | New compounds | |
| MY141528A (en) | Anilinopyrazole derivatives useful for the treatment of diabetes | |
| TW200745044A (en) | Pyrazole derivatives, compositions containing such compounds and methods of use | |
| DE602004006118D1 (de) | 2,3,4,5-TETRAHYDROBENZOiFöi1,4öOXAZEPIN-5-CARBONSÄUREAMID DERIVATE ALS GAMMA-SECRETASE INHIBITOREN ZUR BEHANDLUNG VON ALZHEIMER | |
| ATE412636T1 (de) | Piperazinylpyridinderivate als mittel gegen adipositas | |
| DE602004021363D1 (de) | Imidazotriazin verbindungen zur behandlung von krebserkrankungen | |
| SE0402284D0 (sv) | New heterocyclic amides | |
| ATE424823T1 (de) | 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydrochinolin- derivate als arzneimittel zur behandlung von unfruchtbarkeit | |
| DE602006002608D1 (de) | 4-phenyl-5-oxo-l,4,5,6,7,8-hexahydrochinolin-derivate als arzneimittel zur behandlung von unfruchtbarkeit | |
| EA200701813A1 (ru) | Новые амидозамещенные 6-фенилфенантридины | |
| ATE519740T1 (de) | Tetrahydroindolderivate zur behandlung von alzheimer-krankheit |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |